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Abstract
Context
Diabetic retinopathy (DR) is the leading cause of incident blindness among working-age
adults in the United States. Federally designated safety-net clinics (FDSC) often serve as
point-of-contact for patients least likely to receive recommended DR screenings, creating
opportunity for targeted interventions to increase screening access and compliance.
Study design and methods
With such a goal, we implemented and assessed the longitudinal performance of an FDSC-
based telemedicine DR screening (TDRS) network of 22 clinical sites providing nonmydria-
tic fundus photography with remote interpretation and reporting. Retrospective analysis of
patient encounters between February 2014 and January 2019 was performed to assess
rates of pathology and referral. A generalized estimating equation logistic regression model
was used for subset analysis from audits of pre- and post-implementation screening rates.
Finally, patient surveys were conducted and assessed as a measure of intervention
acceptability.
Results
Of the 13,923 individual telescreening encounters (4327 female, 4220 male, and 5376
unspecified; mean [SD] age, 54.9 [12.5] years) studied, 10,540 were of adequate quality to
identify 3532 (33.5%) patients with ocular pathology: 2319 (22.0%) patients had some level
of DR with 1604 (15.2%) requiring specialist referral, and 808 (7.7%) patients required refer-
ral for other ocular pathologies. The mean screening rate for audited clinics in the year prior
to program implementation was 29.9% (641/2147), which increased to 47.7% (1012/2124)
in the program’s first year, doubling patients’ odds of being screened (OR 2.2; 95% CI: 1.3–
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3.7; P = .003). These gains were sustained over four years following implementation (OR
1.9; 95% CI: 1.1–3.1; P = .018) despite varied clinic screening performance (4-year aver-
aged range, 22.9–55.1%). Odds of early detection likewise doubled for patients with conse-
cutive screenings (OR 2.2, 95% CI: 2.0–2.4; P < .001). Finally, surveyed patients preferred
TDRS to specialist exams (82.5%; 776/941) and would recommend the service to friends
(92.7%; 868/936).
Conclusion and relevance
A statewide, FDSC-centered TDRS network was successfully established and sustained in
a medically underserved region of the United States. Our results suggest that large TDRS
networks in FDSCs can increase screening access and compliance for otherwise
unscreened populations, but outcomes can vary greatly among clinics. Further work to opti-
mize program implementation is needed to maximize this model’s impact.
Introduction
Diabetic retinopathy (DR), a common microvascular complication of diabetes mellitus, is the
leading cause of incident blindness among working-age adults [1]. Annual DR screening with
early intervention can reduce the risk of severe DR-related vision loss by 90% [2–7] and is rec-
ommended by the American Academy of Ophthalmology for all diabetic patients [8]. Yet DR
screening rates in the US remain low [9,10], especially among vulnerable populations [11–14].
These missed opportunities for secondary prevention decrease productivity [15], increase
morbidity [16,17], and increase healthcare expenditures [18,19]. With effective treatments for
DR available, the more intractable challenge has been consistent screening for early identifica-
tion of those requiring closer monitoring or therapeutic intervention.
An estimated 88% of diabetic patients in the US visit their primary care provider (PCP) at
least once per year [20], creating a consistent point of contact for leveraging nonmydriatic fun-
dus photography (nFP) and cloud-based telemedicine to provide DR screenings embedded in
the primary care setting [21]. Telemedicine DR screening (TDRS) may mitigate several of the
known barriers to conventional DR exams, including socioeconomic factors [22–24], geo-
graphic and logistic obstacles [22,25], lack of motivation [22,25], absence of PCP referral
[22,26], inconveniences associated with pupil dilation [27], and specialist availability [24,25].
Images taken in the primary care setting during provision of routine care can be uploaded to
remote specialists for interpretation and as-needed referral. This evidence-based intervention
(EBI) [28] has high sensitivity and specificity,[29,30] making it clinically comparable to the cri-
terion standard for DR screening (in-person specialist-performed dilated fundus exam)
[21,22], and superior to direct ophthalmoscopy performed by PCPs [28,31,32].
Federally designated safety-net clinics (FDSC), including Federally Qualified Health Cen-
ters (FQHC) and rural health clinics (RHC), are cornerstones of the primary care safety-net in
the United States (US), providing vulnerable populations with primary health services and
care coordination. FDSCs are often the only accessible point of care for underserved diabetic
patients [33,34]. To our knowledge, the effectiveness of the TDRS model to increase DR
screening rates in a statewide network of FDSCs exposed to the diverse patient and payer
dynamics of the US health system has not been explored.
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With these facts in mind, we began building a statewide TDRS network in 2013. The part-
nership connected FDSCs across Kentucky to an academic medical center providing low-cost
telemedicine services (image interpretation, reporting, and referral). We herein present and
analyze the network’s implementation process and results, including surveillance data on rates
of DR and non-DR pathologies and effects of continuity of care, from the first five years of the
program. Further, we assess pre- and post-implementation screening rates from a subset of
clinic sites and discuss results of patient surveys intended to assess intervention acceptability.
Methods
The Appalachia Diabetic Eye Network (ADEN) was established as a blindness prevention ini-
tiative to extend DR screening access for underserved populations in Kentucky via primary
care-embedded telemedicine. A collaboration between the Department of Ophthalmology and
Visual Sciences at the University of Kentucky (UKY) and multiple FDSCs across the state, the
ADEN reaches both rural and urban populations.
Both national and state-targeted needs assessments were conducted to establish the justifi-
cation and intervention strategy for the program, and findings were crosswalked to objectives
defined by the World Health Organization’s Healthy People 2020 initiative.
This study conformed to the tenets of the Declaration of Helsinki, was approved by the Uni-
versity of Kentucky’s institutional review board, and was conducted in compliance with the
Health Insurance Portability and Accountability Act.
TDRS program implementation
Clinic recruitment and program integration. During the Pilot phase, FDSC administra-
tors were contacted by a program director (RS) and invited to participate in the program. Clin-
ics were offered nFP cameras, interpretation and reporting services, staff training, and
ongoing technical support free of charge for three years (through grant funding), after which a
nominal fee was charged per screening for interpretation.
An unfunded Expansion phase was opened to meet demand. Clinics were required to inde-
pendently finance the purchase of cameras and were charged the interpretation fee beginning
with their first screening.
The same model nFP camera (Centervue DRS1 desktop nonmydriatic autofocus camera;
Centervue S.p.A, Padova, Italy) was used by all participating clinics of both phases.
As network study sites were recruited, retrospective baseline data was collected from each
regarding their diabetic patient population. Patients were surveyed to assess pre-implementa-
tion patient-perspective attitudes regarding the proposed intervention.
Participating FDSCs were independent or belonged to multi-clinic systems. In some cases,
all clinics in an FDSC system participated in the program, but often not. Such decisions were
left to FDSC leadership and based on the resource constraints, priorities, patient needs, and
provider buy-in idiosyncratic to each site. A model workflow (Fig 1) was developed by pro-
gram directors and distributed to each administration as part of the implementation package
of resources.
To accommodate the heterogeneous administrative and workflow characteristics of net-
work sites, TDRS integration was intentionally made flexible, allowing each site latitude in
adapting the protocols and processes that would govern day-to-day operation of the TDRS
service.
During the study period, all FDSCs provided TDRS to patients as a free service (i.e., not
billed to insurance and triggered no out-of-pocket cost) since cost of care is among the most
significant patient-perceived barriers to TDRS utilization [22].
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Patient recruitment. We performed a retrospective electronic chart review of all patients
who participated in the ADEN program between February 01, 2014 and January 31, 2019.
According to the screening protocol, all nonpregnant adults with types 1 or 2 diabetes and
without a complete eye exam or DR screening documented during the prior 12 months should
be offered TDRS in clinic during regularly scheduled appointments (Fig 1).
Imaging
Pre-existing clinic staff were trained to use the screening protocol (Fig 1). nFP training was
completed in single sessions simultaneous with installation of the camera systems on site by
company (Centervue) representatives and trainers.
Staff performed image captures using a 45˚ field of view centered between the optic disc
and fovea (Central Nasal) to include the optic disc, macula, and vascular arcades. One image
per eye was uploaded to a secure cloud storage server. The interpretations were performed by
Fig 1. Appalachia Diabetic Retinopathy Network TDRS Clinical Workflow Model. The clinical workflow distributed to ADEN sites begins with the
identification of diabetic patients, and walks through the key questions (white), actions (green), and end-points (red) to be completed for each
encounter. Abbreviations: TDRS, Telemedicine diabetic retinopathy screening; EMR, Electronic medical record; nFP, Nonmydriatic fundus
photography; DR, Diabetic retinopathy.
https://doi.org/10.1371/journal.pone.0241767.g001
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the partner institution (UKY) utilizing REDCap software (Research Electronic Data Capture;
Vanderbilt University, Nashville, Tennessee, USA).
Image interpretation
Images were reviewed and interpreted by UKY retina specialists without access to clinics’ elec-
tronic medical record (EMR) systems. Specialists noted whether each image was gradable or
ungradable, the absence or presence and severity of DR, the absence or presence of diabetic
macular edema, as well as findings concerning for nondiabetic pathologies considered by the
grading ophthalmologist to be life- or sight-threatening. DR severity was graded according to
the International Clinical Disease Severity Scales for DR and DME (Table 1) [35]. When evi-
dence of DR was observed in both eyes, the patient’s overall severity was defined by the more
severe grade. If at least one image showed referable pathology, a referral for that purpose was
made. An image was considered ungradable if both 1) no signs of pathology were discernible
in viewable areas, and 2) subtle pathology could not be ruled out for at least 60% of the macula.
The program met the American Telemedicine Association’s criteria for Validation Category 3
[36].
Reading center reporting and recommendations
Reports with follow-up and referral recommendations were sent to point-of-care clinics.
Referrals were based on the presence and level of DR, the presence of non-DR findings (or
both, when appropriate), and if one or both of the images were ungradable.
Patients without pathology or with mild nonproliferative diabetic retinopathy (NPDR)
were recommended for repeat exam in 12 months. Patients with moderate NPDR were
referred to an eye care provider to be seen within 3 months, while those with severe NPDR,
proliferative DR, or diabetic macular edema (DME) were referred to a retina specialist to be
seen within 1 month. Urgency of referral for other pathologies was determined case-by-case.
For patients with ungradable or missing images, a referral for dilated ocular examination by an
eye care specialist within three months was recommended.
Screening rates
Pre- and post-implementation screening rates were provided by a subgroup of six Pilot phase
clinics. Screening rates per year were calculated using clinic electronic medical record (EMR)
Table 1. International Clinical Diabetic Retinopathy and Diabetic Macular Edema Disease Severity Scales.
Classification Observable Findings
No apparent retinopathy No abnormalities
Mild nonproliferative diabetic
retinopathy
Microaneurysms only
Moderate nonproliferative diabetic
retinopathy
More than just microaneurysms but less than severe nonproliferative diabetic
retinopathy
Severe nonproliferative diabetic
retinopathy
Any of the following: more than 20 intraretinal hemorrhages in each of 4
quadrants; definite venous beading in 2+ quadrants; Prominent intraretinal
microvascular abnormalities in 1+ quadrant and no signs of proliferative
retinopathy
Proliferative diabetic retinopathy One or more of the following: neovascularization, vitreous/preretinal
hemorrhage
No apparent macular edema No apparent retinal thickening or hard exudates in posterior pole
Diabetic macular edema is present Some apparent retinal thickening or hard exudates in posterior pole
https://doi.org/10.1371/journal.pone.0241767.t001
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queries as: number of diabetic patients with documented DR screening within 12 months /
total number of diabetic patients with at least one clinical encounter during the same period.
Patient survey
Patient acceptability of TDRS was assessed using a questionnaire offered to all screened
patients at Pilot phase clinics between March 2014 and March 2017, along with a waiver of
informed consent. Patient participation was voluntary. The instrument was developed by pro-
gram directors (RS and EBH) and reviewed by program staff for clarity. The survey instrument
was optionally presented in paper and web-based modes depending on clinic and patient pref-
erence(s), captured no identifying information, and was submitted anonymously. Electronic
versions were uploaded directly and stored using REDCap software on UKY secure servers;
paper versions were shredded after being transcoded to the research database.
Analysis
Descriptive analyses were conducted for frequencies and percentages of pathologies. Because
pathology could not be ruled out for ungradable images, the screening positive rate was calcu-
lated using the number of adequate screenings in the denominator, which may provide a more
accurate estimate of disease burden in the screened population.
A univariate logistic regression model was used to determine the odds ratios (ORs) and
95% confidence intervals (CIs) for the association between patients’ age and adequate imaging
(gradeability). A generalized estimating equation logistic regression model was used to analyze
repeated screening rate measures for pre- and post-intervention periods. From patient surveys,
patients’ self-reported characteristics and satisfaction responses were analyzed, with p-values
calculated using Chi-square and Fisher’s exact tests, as appropriate. Missing observations were
excluded on an analysis-by-analysis basis. Statistical significance was determined as p-values <
.05 (two-tailed) for all tests. All analyses were performed using Statistical Analysis Software
(SAS), version 9.4 (SAS Institute, Cary, NC, USA).
Results
Program implementation
Two FDSC systems constituting 11 clinical sites were initially recruited and signed grant con-
tracts. All sites received the implementation package, nFP cameras, and image interpretation
services as the Pilot phase cohort of clinics (Table 2). Subsequently, 11 more FDSC clinics
Table 2. Timeline of TDRS clinic rollout.
Clinic Site Study Phase Rollout Date
Clinics 1–4 Pilot February 2014
Clinics 5–7 Pilot November 2014
Clinic 8 Expansion May 2015
Clinic 9 Expansion August 2015
Clinics 10, 11 Pilot December 2015
Clinics 12, 13 Pilot February 2016
Clinic 14 Expansion February 2016
Clinic 15 Expansion August 2016
Clinics 16, 17 Expansion June 2017
Clinics 18–22 Expansion December 2017
Abbreviations: TDRS, Telemedicine diabetic retinopathy screening.
https://doi.org/10.1371/journal.pone.0241767.t002
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petitioned for participation in the network. All qualified and were included in the Expansion
phase (Table 2). Over the period studied, all 22 clinics remained in the network, registering a
100% clinic retention rate, and all clinics continued to offer the service free-of-charge to
patients throughout and following the study period. In many clinics, costs were offset by gains
in performance-based bundled-care bonuses.
This network of 22 FDSCs was comprised of 6 FQHC and 1 RHC multi-site systems, with
an average of 3 participating clinics each, and 1 single-site FQHC. Clinics averaged 5.9 provid-
ers per site (range: 3–12), and all but the 5 urban sites served rural populations. All clinics had
EMR systems and broadband access.
Demographics
During the program’s first five years, a total of 13,923 TDRS exams were completed (Table 3),
serving 10,056 unique patients (dataset available as a S1 Dataset). Mean patient age was 54.9
years (SD 12.5 for 13,767 records), and gender was evenly balanced (male 49.4%, female 50.6%
of 8547 records).
Gradeability
Of the 13,923 exams performed, 10,540 were of sufficient quality to either rule out DR, or iden-
tify a life- or sight-threatening pathology requiring referral. We therefore report a practical
gradeability (adequacy) rate of 75.7%, with annual gradable exam rates among individual clin-
ics ranging between 65.7% and 92.7%. As expected, a significant correlation was observed
between odds of gradeability and age. Probability that a screening would result in referral due
to ungradable image(s) increased 5% for every 1 year increase in patient age (odds ratio: 1.1;
95% CI: 1.0–1.1).
Pathology
Sixty-six percent (7008/10,540) of adequate exams had no discernible pathology. Diabetic reti-
nopathy was identified in 22.0% of adequate exams (2319/10,540; 2276 with DR and 536 with
DME, 499 of which overlapped) (Table 4). When defined by degree of retinopathy in the worst
affected eye, 66.9% (1523/2276) of those with DR had mild NPDR; 18.1% (411/2276) had mod-
erate NPDR; 10.5% (238/2,276) had severe NPDR; and 4.6% (104/2276) had proliferative DR.
DME was present in 5.1% (536/10,540) of adequate screenings.
Table 3. Number of TDRS encounters by year.
Year Frequency Proportion (%)
2014a 656 4.71
2015 2,061 14.80
2016 3,243 23.29
2017 3,540 25.43
2018 3,860 27.72
2019b 563 4.04
Total 13,923 100
aNetwork screening began with 4 clinics in February 2014.
bCutoff for analysis was January 31st 2019.
Abbreviations: TDRS, Telemedicine diabetic retinopathy screening.
https://doi.org/10.1371/journal.pone.0241767.t003
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Incidental findings nonspecific to diabetes were observed in 11.5% (1213/10,540) of ade-
quate screenings. AMD suspect (5.0%; 530/10,540) and glaucomatous findings (2.5%; 268/
10,540) were most commonly observed, followed by vascular occlusion (0.6%), macular scar-
ring (0.6%), and epiretinal membrane (0.5%) (Fig 2).
Referrals
In total, 5709 patients were recommended for follow-up or specialist referral (Fig 3). The over-
all rate of referral was 41.0% (5709 of 13,923 exams). The most common reason for referral
was insufficient image quality (59.3%; 3383/5709), followed by diabetic pathology (28.1%;
1604/5709) and non-diabetic pathology (14.2%; 808/5709), with 86 overlapping.
Regarding urgency of referral, less than 1% of referrals were considered urgent (0.8%; 45/
5709), 12.5% of referred patients were to be seen within 1 month (711/5709), and 86.8% (4953/
5709) were to be seen within 3 months of screening (Fig 4).
Of the 5709 referrals analyzed, 8.9% were to retina specialists (509/5709), and 1.9%
(110/5709) designated general ophthalmologist as the appropriate provider type. The
remaining were for any eye care provider (ophthalmologist or optometrist; 89.2%; 5090/5709)
(Fig 5).
Table 4. Presence and severity of diabetic eye disease.
Disease Total Exams (N = 13,923), n (%) Adequate Exams (N = 10,540), % DR-Positive Exams (N = 2319), %
No DR 8221 (59.05) 78.0
Any DR 2276 (16.35) 21.6 98.2
Mild NPDR 1523 (10.94) 14.5 65.7
Moderate NPDR 411 (2.95) 3.9 17.7
Severe NPDR 238 (1.71) 2.3 10.3
Proliferative DR 104 (0.75) 1.0 4.5
Macular Edema 536 (3.85) 5.1 23.1
Abbreviations: DR, Diabetic retinopathy; NPDR, Nonproliferative diabetic retinopathy.
https://doi.org/10.1371/journal.pone.0241767.t004
Fig 2. Selected incidental findings. �Other less common findings included cataract or media opacity, macular dystrophy,
Hollenhorst plaque, macular hole, crystalline maculopathy, choroid scar, myelinated nerve fiber layer, asteroid hyalosis or vitreous
debris, hypertensive retinopathy, myopic degeneration, optic nerve head elevation, retinal degeneration, and more. Abbreviations:
AMD, Age-related macular degeneration; RPE, Retinal pigment epithelium.
https://doi.org/10.1371/journal.pone.0241767.g002
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Care continuity
During the 5-year timeframe analyzed, 2699 patients (26.8%) received two or more in-clinic
screenings, accounting for 47.2% (6577/13,923) of all TDRS performed.
There was a significant difference in the proportion of referable DR pathology between sin-
gle- and multiple-visit groups (12.9% and 24.3%, respectively; (P< .001)), suggesting that con-
tinuity of screening services doubled the odds of early detection of referable DR pathology
(OR 2.2, 95% CI: 2.0–2.4; P< .001). Interestingly, the odds of future in-network screenings
increased following the second TDRS encounter (OR 1.3, 95% CI: 1.2, 1.4; P< .001).
Screening rates
DR screening rates increased in all audited clinics following TDRS implementation, though
not all clinics sustained their initial gains (Fig 6). Screening rates in the year prior to imple-
mentation averaged 29.9% and ranged from 16.8% to 47.4%. The mean first-year screening
rate increase was 18.5%, which, in a generalized estimating equation logistic regression model,
Fig 3. Reasons for referral to an eye care provider. Abbreviations: DR, Diabetic retinopathy.
https://doi.org/10.1371/journal.pone.0241767.g003
Fig 4. Urgency of referral to an eye care provider.
https://doi.org/10.1371/journal.pone.0241767.g004
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doubled patients’ odds of being screened over the previous year (OR 2.2; 95% CI: 1.3–3.7; P =
.003). Sustained screening rate gains averaged 14.0% (Table 5) and diabetic patients were 87%
more likely to be screened for DR during the four years following implementation than they
had been before TDRS implementation (OR 1.9; 95% CI: 1.1–3.1; P = .018).
Patient satisfaction
Nine hundred fifty-two patients completed a TDRS satisfaction survey post-screening. Three
quarters of those responding (73.2%; 522/713) were in their first decade since diagnosis, and
approximately half (48.3%; 263/545) self-reported that their diabetes was well-controlled.
Regarding TDRS, 92% (869/941) were satisfied with the screening experience; 82.5% (776/941)
preferred the primary-care based TDRS service over visiting an eye care specialist; and 92.7%
Fig 5. Referred provider types.
https://doi.org/10.1371/journal.pone.0241767.g005
Fig 6. Comparison of diabetic retinopathy screening rates over time for adult diabetic patients among sampled
clinics before and after implementation. Six audited ADEN clinics are shown, with time of TDRS program
implementation represented by time 0 for all clinics. Actual implementation was on a rolling basis covering a 2 year
period between February 2014 and February 2016. Abbreviations: DR, Diabetic retinopathy; TDRS, Telemedicine
diabetic retinopathy screening.
https://doi.org/10.1371/journal.pone.0241767.g006
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(868/936) would recommend TDRS to friends with diabetes. Similar large majorities rated the
service convenient (94.5%; 885/937), comfortable (90.2%; 847/939), quick (94.0%; 877/933),
and easy (93.8%; 879/937; Table 6). We observed a significant inverse correlation between
duration of diabetes and HbA1c control (P = .002), and a positive correlation between HbA1c
control and overall satisfaction with the TDRS experience (P = .02).
Discussion
DR screening rates in the US remain low due to patient-, provider-, clinic-, and system-level
barriers. Many such barriers may be mitigated through convenient primary care-based tele-
screening [29,37], which has been shown to increase DR screening rates [21].
In this analysis of nearly fourteen thousand TDRS encounters during the first 5 years of an
academic-community partnership of 22 FDSC sites serving rural and urban poor communities
in Kentucky, the need for over 8000 specialist exams was eliminated; more than 2000 referable
pathologies were detected; odds of patients’ being screened doubled, and gains were sustained
over years; care continuity doubled the odds of early detection of referable pathology and
increased odds of future screening compliance; and most patients preferred and endorsed the
intervention over traditional specialist exams.
Regarding TDRS image gradeability, over ten thousand screenings adequate for detection
of DR and other pathologies were performed, for a gradeability rate above 75%. This is just
below the range observed in some similar studies of nFP screenings. For example, Gao et al., in
Table 5. Annual rates of DR screening before and after TDRS program implementation.
Diabetic patients, No./Total No., (%)
Clinic Pre-interventiona Post-interventionb Sustained increase in proportion screened, %
Clinic A 56/288 (19.4) 428/1155 (37.1) 17.6
Clinic B 65/388 (16.8) 861/1536 (55.1) 39.3
Clinic C 225/475 (47.4) 973/1954 (49.8) 2.4
Clinic D 183/514 (35.6) 888/1980 (44.9) 9.3
Clinic E 51/208 (24.5) 410/865 (47.4) 22.9
Clinic F 61/274 (22.3) 304/1329 (22.9) 0.6
TOTAL 641/2147 (29.9) 3864/8819 (43.8) 14.0
aRate reported during the year prior to TDRS implementation.
bAverage rate over first four years following TDRS implementation.
Abbreviations: DR, Diabetic retinopathy; TDRS, Telemedicine diabetic retinopathy screening.
https://doi.org/10.1371/journal.pone.0241767.t005
Table 6. Self-reported patient satisfaction with in-clinic TDRS experience.
Prompt Responses Agree or strongly agree Proportion of responses favorable of TDRS, %
I was satisfied with my eye exam experience. 941 868 92.2
I prefer this screening over visiting an eye doctor. 941 776 82.5
I would recommend this screening to friends with diabetes. 936 868 92.7
This exam was convenient. 937 885 94.5
This exam was comfortable. 939 847 90.2
This exam was quick. 933 877 94.0
This exam was easy. 937 879 93.8
Abbreviations: TDRS, Telemedicine diabetic retinopathy screening.
https://doi.org/10.1371/journal.pone.0241767.t006
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a study of an urban primary care practice network with academic affiliations, observed a prac-
tical gradeability rate of 76.7% after accounting for both missing and inadequate images [38].
Chin et al., in comparing TDRS outcomes between a rural Native American Indian population
and patients of an urban family practice identified 82.4 and 85.7% of images adequate for eval-
uation, respectively [39]. The inverse correlation between age and gradeability (observed here
and corroborated elsewhere) [40] may explain some proportion of the ungradable images in
this study, but given the wide range of rates over time and among clinics, we hypothesize that
inconsistent image quality is at least partly due to multilevel barriers and inadequate imple-
mentation strategies that warrant further elucidation.
Diabetic pathology was found in 22% of adequate screenings. Other studies of TDRS pro-
grams in the US have reported similar DR rates [27,38,39,41–45], with rate variations likely
tracking with variations in socioecological determinants [46].
More than 95% of screenings positive for DR were for non-proliferative DR (NPDR), sug-
gesting an exceptional opportunity for providers to forestall disease progression before irre-
versible vision loss occurs. The proportion of adequately screened patients with proliferative
DR (PDR; 1.0%, 95% CI: 0.8–1.2) was higher than that observed by Gao et al. (0.2%, 95% CI:
0.2–0.4) [38]. Evidence of diabetic macular edema (DME) was more common still (5.1%, 95%
CI: 4.7–5.5), present in 23.0% of pathology-positive referrals. This DME rate is higher than
that reported by Gao et al. (0.4%, 95% CI: 0.3–0.5) [38], but similar to rates observed by Gu
et al. (4.4%, 95% CI: 2.4–7.4) and Varma et al. (3.8%, 95% CI: 2.7–4.9) [27,47]. These dispari-
ties may be the result of study population differences in diabetes duration, glycemic control,
and screening compliance.
Almost 12% of adequate screenings revealed non-diabetic pathology, including intermedi-
ate stage or higher AMD and glaucoma. Such incidental findings of potentially disabling dis-
eases increase the value of DR screening generally, and TDRS specifically, by reaching patients
not otherwise receiving appropriate eye care.
Our observation that the odds for early detection of referable DR pathology were doubled
by screening service continuity (OR 2.2, P< .001) reinforces both the value of the annual
screening schedule and the importance of TDRS program sustainment. In concert, our obser-
vation that the odds of future in-network screenings increased following the second annual
visit (OR 1.3, P< .001) suggests a small but significant cumulative effect of patient education
and expectation on service utilization. Nevertheless, aggregate rates never approached the
National Committee for Quality Assurance’s Diabetes Recognition threshold of 60%, pointing
to higher level and upstream factors barring greater implementation effectiveness. Unfortu-
nately, few studies of TDRS report follow-up screening rates over the large timeframe herein
described [48], limiting opportunities for relevant comparison.
In contrast, a wide range of results have been published on the impact of TDRS for overall
screening rates [42,49–53]. Of note, very few of these studies report on as large a network of
clinics, or span both rural and urban poor populations, or surveille an equivalent timeframe.
Taking our network in aggregate, the 1-year doubling of odds for being screened (OR 2.2; 95%
CI: 1.3–3.7; P = .003) was similar to the increase described by Daskivich et al. for a safety-net
system (OR 1.9; 95% CI: 1.3–2.9; P = .002) [54]. Our study also found a sustained pooled
screening rate gain of 14% (95% CI: 11.7–16.1; P< 0.001) over four years, similar to the
improvement observed by Jani et al. (15.8%; 95% CI: 13.0–16.6) [41], though that increase was
reported only for the first year after implementation and regarded a smaller cohort of five
clinics.
Despite large increases in screening rates for some of our clinics, others improved little.
Further, gains were sustained in some clinics, whereas others’ performance regressed over
time. These differences in TDRS adoption and sustainment reflect the challenges to
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implementation across disparate contexts and practices and point to unidentified upstream,
multi-level variables affecting program success. Prior research on TDRS has mainly focused on
patient-level factors influencing screening compliance, with scarce data on higher-level barri-
ers.[55] Addressing this paucity, Liu et al. recently used content analysis methods with open-
ended interviews of rural PCPs involved in TDRS delivery to identify several perceived pro-
vider-level barriers, including difficulty identifying when patients are due for screening, time
constraints, and difficulty of referrals.[56] Barriers anecdotally observed during implementa-
tion of TDRS in a large urban safety-net system were reported by Ogunyemi et al. to include
poor workflow integration, inadequate patient education, inconsistent image quality, and staff
diversion.[57] Any, all, or none of these may explain the range of program outcomes we
observed, and the identification of factors determining TDRS program success is a priority of
our ongoing work.
One potential barrier that our patient survey data refutes is patient objection. Surveyed
patients preferred TDRS to specialist exam and endorsed TDRS to friends, indicating a high
patient valuation of the TDRS model [22].
Our study provides novel insights for state-scale TDRS implementation targeting under-
served populations. To our knowledge, no other longitudinal studies in the US have described
a TDRS network as geographically and administratively diverse, nor demonstrated sustained
multi-year impact on screening rates, nor quantified patient-level effects of care continuity for
odds of early detection and odds of future screening compliance. Combined, our findings pro-
vide a useful framework for other stakeholders to implement sustainable large-scale TDRS
programs compatible with social distancing, appropriate for vulnerable populations, and syn-
ergistic with care continuity.
Limitations
Though very few patients refused the TDRS service when offered, the studied pool was neces-
sarily limited to those attending a network clinic for care, creating a potential selection bias by
exclusion. Image quality, media opacities, and peripheral exclusion due to limited field of view
each contributed to potential underestimates of pathologies.
The structure of our academic-community network prevented the efficient sharing of medi-
cal record data. The resulting paucity in demographic and clinical data is a limitation that pre-
cluded regression analysis to identify patient-level predictors of screening outcomes. Further,
because most clinics served communities far from our academic system and referrals were
therefore directed to outside specialists, we were unable to assess whether patients sought or
received referred eye care—a target of our ongoing studies.
These limitations reflect the intrinsic nature of studies involving low-resource community
partnerships. While they may limit generalizability, our study describes a strategy for large-
scale TDRS implementation in FDSCs; advances understanding of outcomes of TDRS services
for underserved populations; and lays the foundation for future research on barriers and facili-
tators of optimal TDRS implementation in the safety-net primary care setting.
Conclusions
This report demonstrates that TDRS embedded in FDSCs can reduce the need for specialist
appointments, increase patients’ odds of screening and early detection of vision-threatening
pathology, and achieve sustained increases in screening rates for underserved populations.
Despite high patient acceptability, screening rates across our clinics were variable and aggre-
gate performance lagged the national DR screening rate, suggesting that to achieve full inter-
vention potential, optimal implementation is essential.
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Future studies should address poorly understood barriers to TDRS implementation at the
level of professionals, healthcare institutions, and payer systems.
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